09:52 AM EDT, 10/22/2024 (MT Newswires) -- Ocugen ( OCGN ) said Tuesday that the Data and Safety Monitoring Board for its phase 1/2 clinical trial of CU410ST to treat Stargardt disease has approved enrollment for the trial's second phase.

Stargardt disease is a genetic eye disorder that causes retinal degeneration and vision loss.

The biotech firm also said there were no serious adverse events reported for the first phase of the trial.